Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries

作者：Choong‐kun Lee, Changhoon Yoo, Jung Yong Hong, Se Jun Park, Jin Won Kim, David Wai Meng Tai, Hyeyeong Kim, Krittiya Korphaisarn, Suebpong Tanasanvimon, San‐Chi Chen, Ju Kim, Il Hwan Kim, Moonho Kim, Joan Choo, Sang-Bo Oh, Ching-Tso Chen, Woo Kyun Bae, Hong-Sik Kim, Seok Jae Huh, Chia‐Jui Yen, Sejung Park, Dong Ki Lee, Landon L. Chan, Beodeul Kang, Minsu Kang, Raghav Sundar, Hye Jin Choi, Stephen L. Chan, Hong Jae Chon, Myung Ah Lee · 发表于：Liver Cancer · 年份：2024 · DOI：10.1159/000540969 · 被引用次数：14 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Cholangiocarcinoma and Gallbladder Cancer Studies、Cancer Mechanisms and Therapy

Introduction: Atezolizumab plus bevacizumab is a commonly used first-line regimen for advanced hepatocellular carcinoma (HCC) treatment owing to its superior outcomes compared to sorafenib. However, optimal subsequent treatment options for patients with HCC who progressed on first-line atezolizumab plus bevacizumab remain unclear. Methods: This multinational, multi-institutional, retrospective study included patients with HCC from 22 centers in five Asia-Pacific countries who were treated with first-line atezolizumab plus bevacizumab, which was discontinued for any reason. The endpoints included progression-free survival (PFS) and overall survival (OS) according to patient characteristics and second-line regimens. Results: Between June 2016 and May 2023, 1,141 patients were treated with first-line atezolizumab plus bevacizumab, of whom 629 (55.1%) received subsequent treatment. Sorafenib and lenvatinib were the most commonly administered second-line regimens (53.9% and 25.6%, respectively). Overall, the median PFS and OS were 2.9 and 8.0 months, respectively. Lenvatinib had longer PFS (4.0 vs. 2.3 months) and OS (8.0 vs. 6.3 months) than sorafenib. Patients treated with tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI) (n = 50, 8.3%) showed PFS and OS of 5.4 and 12.6 months, respectively. Lower tumor burden and lenvatinib or TKI plus ICI use were associated with longer second-line PFS. Preserved liver function was associated with improved OS. Conclusions:...